WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids

American Journal of Clinical Pathology

Volumn 117, Issue 5, 2002, Pages 745-750

  Lee, Benjamin H ^a   Hecht, Jonathan L ^a   Pinkus, Jack L ^a   Pinkus, Geraldine S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Body fluids; Cell block; Cytology; Estrogen; Estrogen receptor; Gross cystic disease fluid protein; Progesterone; Progesterone receptor; WT1

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GROSS CYSTIC DISEASE FLUID PROTEIN; HORMONE RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN WT1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; ASCITES; BODY FLUID; BREAST CANCER; BREAST CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EFFUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; LUNG CANCER; METASTASIS; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; APOLIPOPROTEINS; APOLIPOPROTEINS D; ASCITIC FLUID; BODY FLUIDS; BREAST NEOPLASMS; CARRIER PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MEMBRANE TRANSPORT PROTEINS; OVARIAN NEOPLASMS; PERICARDIAL EFFUSION; PLEURAL EFFUSION, MALIGNANT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 0036233031     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/QLV6-HH0H-UCTF-WEF6     Document Type: Article

References (20)

1. Positive effusion cytology as the initial presentation of malignancy
2. Use of antibodies against estrogen and progesterone receptors to identify metastatic breast and ovarian carcinomas by conventional immunohistochemical and tyramide signal amplification methods
3. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas
4. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin
5. Gross cystic disease fluid protein- 15 as a marker for breast cancer: Immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin
6. Adenocarcinoma in the lung in patients with breast cancer: A prospective analysis of the discriminatory value of immunohistology
7. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases
8. Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas
9. Cytokeratin 20 in human carcinomas: A new histodiagnostic marker detected by monoclonal antibodies
10. Immunohistochemical demonstration of keratin 7 in routinely fixed paraffin-embedded human tissues
11. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma: A diagnostic adjunct in the determination of primary site
12. Immunohistologic evaluation of metastatic carcinomas of unknown origin: An algorithmic approach
13. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinoma
14. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
15. Wilms' tumour gene and function
16. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis
17. Immunohistochemical detection of the Wilms' tumor gene (WTI) in epithelial ovarian tumors
18. The value of WT1 in cytologic preparations as a marker for malignant mesothelioma
19. The immunohistochemical diagnosis of epithelial mesothelioma
20. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma